AUPH Q3 2024 Earnings — Aurinia Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

AUPHAurinia Pharmaceuticals Inc.

$2B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$68M+24.3% YoY

Gross Profit

$62M91.1% margin

Operating Income

$12M17.3% margin

Net Income

$14M21.2% margin

EPS (Diluted)

$0.10

QoQ Revenue Growth

+18.5%

Cash Flow

Operating Cash Flow

$17M

Free Cash Flow

$17M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$549M

Total Liabilities

$161M

Stockholders' Equity

$388M

Cash & Equivalents

$37M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$68M	$55M	+24.3%
Gross Profit	$62M	$48M	+29.3%
Operating Income	$12M	-$16M	+172.2%
Net Income	$14M	-$13M	+206.7%

Revenue Segments

Product

$56M82%

License, Royalty and Collaboration Revenue

$12M18%